Liver Cancer Therapeutics Market to 2018 - Nexavar, the
Only Approved Targeted Therapy for Advanced Disease, Continues to
Dominate as Other Late Stage Trials Fail
Summary
Leading business intelligence provider, GBI Research, has released
its latest research report, entitled: “Liver Cancer Therapeutics Market
to 2018 - Nexavar, the Only Approved Targeted Therapy for Advanced
Disease, Continues to Dominate as Other Late Stage Trials Fail”. The
report provides insights into the liver cancer therapeutics market in
the US, the top five European countries (the UK, Germany, France, Italy
and Spain) and Japan, with market forecasts until 2018. It provides
in-depth analysis of the major marketed products, as well as insights
into the liver cancer therapeutics R&D pipeline. The report also
gives in-depth analysis of the unmet needs, drivers and barriers that
affect the markets in these countries. Additionally, it discusses the
global pipeline for all the liver cancer molecules across various stages
of development.
To Read The Complete Report with TOC Kindly Visit: http://www.marketresearchreports.biz/analysis/158133
The report is built using data and information sourced from
proprietary databases, primary and secondary research and in-house
analysis by GBI Research’s team of industry experts.
GBI Research found that the liver cancer therapeutics in the top
seven markets (the US, the UK, Germany, France, Spain, Italy and Japan)
was estimated at $374.3m in 2011, having grown at a Compound Annual
Growth Rate (CAGR) of 21.7% from 2004. Growth was driven by an increase
in the patient volume and the Annual Cost of Therapy (ACT) per patient,
which increased due to the approval of Nexavar (sorafenib) in the US and
Europe. The market is forecast to reach revenues of $644.3m by 2018,
growing at a CAGR of 8.1% from 2011.
For All Latest Reports Kindly Visit: http://www.marketresearchreports.biz/latest
The current competition in the liver cancer market is weak, as
Nexavar is the only drug approved for advanced Hepatocellular Carcinoma
(HCC) with the exception of Miripla (miriplatin) in Japan. However,
there are some molecules in Phase III development as first-line and
second-line treatments which promise to influence the competitive
landscape in the next two to three years. The anticipated launch of Eli
Lilly's ramucirumab (IMC-1121B), a monoclonal antibody in 2014; Celsion
Corporation's ThermoDox in 2014; and PrevOnco in 2015 will drive the
market forward.
Scope
- Annualized market data for the liver cancer therapeutics market from 2004 to 2011 and forecast to 2018
- Analysis of the liver cancer therapeutics market in the leading geographies of the world: the US, the UK, Germany, France, Italy, Spain, and Japan
- Market characterization of the liver cancer therapeutics market including market size, annual cost of therapy and treatment usage patterns
- Key drivers and barriers that affect the market
- Coverage of pipeline molecules in various Phases of drug development
- Competitive benchmarking of leading companies including Bayer and Dainippon Sumitomo Pharma
- Key M&A activities and licensing agreements that have taken place between 2008 and October 2012 in liver cancer therapeutics in the top seven markets
Reasons to buy
- Align your product portfolio to the markets with high growth potential
- Develop market-entry and market-expansion strategies by identifying the regions and market segments poised for strong growth
- Create a more tailored country strategy through the understanding of key drivers and barriers of the liver cancer therapeutics market
- Develop key strategic initiatives by understanding the key focus areas and top-selling products of leading companies
- Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships
No comments:
Post a Comment